# A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy

> **NCT05178576** · PHASE2 · WITHDRAWN · sponsor: **NSABP Foundation Inc**

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** Gevokizumab
- **DIAGNOSTIC_TEST:** Signatera test

## Key facts

- **NCT ID:** NCT05178576
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-24
- **Primary completion:** 2026-02
- **Final completion:** 2027-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study drug not available for the study duration.
- **Last updated:** 2022-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178576, "A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05178576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*